About Regenexx - Regenexx®

Regenexx® Information

We envision a future where 90% of what’s currently done through surgery will be accomplished through an injection. Where regenerative procedures are the norm, rather than the exception. Where patients walk-in and walk-out from their orthopedic procedures with minimal, if any, downtime.


Where everyone has access to the safest and most effective treatments available.

About Regenexx

Regenexx is a national network of musculoskeletal doctors specializing in the nation’s most advanced regenerative medicine protocols, developed and patented by Regenexx.  We have developed a family of medical procedures that use a person’s own stem cells and blood growth factors to help treat musculoskeletal injuries and degenerative conditions. Our physicians practice “Interventional Orthopedics” by providing non-surgical biologic therapies delivered with high accuracy through a needle.

We believe in educating patients, providing choices, offering options and encouraging people to take an active role in their own treatment. We strive to improve the quality of life for each patient through compassion, dedication and innovative treatment plans designed to meet the individual needs of the patient.

Executive Bios

Christopher J. Centeno, M.D.

Christopher J. Centeno, M.D. is an international expert and specialist in regenerative medicine and the clinical use of mesenchymal stem cells in orthopedics.  He is board certified in physical medicine and in pain managementDr. Centeno is one of the few physicians in the world with extensive experience in the culture expansion of and clinical use of adult stem cells to treat orthopedic injuries. He and his partner John Schultz were the first physicians in the US to use culture expanded stem cells in patients through an IRB approved study that spanned 2005-2007. He is a founding member of the International Cellular Medicine Society.  Dr. Centeno treats patients from all over the US who travel to Colorado to under-go innovative, non-surgical treatments. Dr. Centeno has chaired multiple international research based conferences.  He also maintains an active research based practice, with multiple publications listed in the US National Library of Medicine.  Dr. Centeno has also served as editor-in-chief of a medical research journal dedicated to traumatic injury.

Dr. Centeno trained at the Baylor College of Medicine, Texas Medical Center and the Institute for Rehabilitation Research.  He hails from both Florida and New York and currently resides in Boulder, Colorado with his wife and three children.


John Schultz, MD

Dr. Schultz is widely experienced in percutaneous treatment of musculoskeletal disorders, including localized adult stem cell therapy.  He plays a crucial role in training physicians to use the Regenexx® procedure. His wide experience with patients with musculoskeletal disorders allows him to play a significant role in physician outreach.

John earned his medical degree from George Washington University and he completed his residency in anesthesiology at the University of Utah.  He further specialized during two fellowships in pain management and critical care medicine. He is double board certified in pain medicine and anesthesia.

Regenexx History - Written by Dr. Chris Centeno

Dr. Chris Centeno on the History of Regenexx

Regenexx began in 2005, when I noticed a research paper that used mesenchymal stem cells (MSCs) to repair degenerated discs in rabbits. The concept was exciting, as the paper showed that even badly degenerated discs could be made new again by injecting stem cells. At the time, our clinic cared for hundreds of patients each year that could benefit from this technology, as the only surgical option was a fusion or artificial disc replacement, both potentially side effect laden procedures with low success rates. I contacted a local university professor who had experience in using MSCs to treat joint and tendon problems in athletic horses and began a two year process of applying a similar technology to our patients.

For the first two years, we performed an IRB approved study to treat degenerated discs and arthritic joints. During this time we didn’t charge for any care and self-funded the study. After that we were convinced that we were seeing good results in many of the joint arthritis patients, but the disc patients weren’t responding. As a result, in late 2007 we began to treat patients with their own stem cells. This was with both cells that were isolated and placed back the same day as well as a more advanced procedure where the cells were cultured to greater numbers. Later in 2009, once we made substantial changes to the process, we were able to help patients with bulging discs through injecting stem cells.

Since 2007, we have treated thousands of patients with stem cells that are tracked in a treatment registry for clinical outcomes and complications. We have published numerous peer reviewed papers on our different procedures applied to joint arthritis, tendon/ligament tears, and fracture non-unions. We publish this registry data on our web-site by area treated, so patients get a reliable sense of what to expect from each procedure.

We also have a full time biostatistician who uses the data from our registry to answer key questions-such as which dose of stem cells produces the best results? Our clinical research team publishes several research papers a year and our company has self-funded several randomized controlled trials that are in process. Right now, we are recruiting patients for studies on using stem cells to treat knee ACL injuries, shoulder rotator cuff tears, knee arthritis, and sciatica. Our low back disc technology was licensed to a publicly traded company that is pursuing full FDA approval for a device and that novel cultured cell technology.

While in many parts of the world, cultured stem cells are considered tissue and the procedures are considered the practice of medicine, even though this is tissue from the same patient in which it will be used, in the U.S. they have been declared a drug. As a result, we stopped offering our cultured stem cell procedures in Colorado in 2010 and licensed that technology to a clinic and lab in Grand Cayman who now offers that procedure. Despite that, we offer the same day stem cell procedures that are allowed here in the U.S. and we’ve found these to be effective in many orthopedic injuries.

In 2012, in order to meet a growing demand for our procedures, we began the Regenexx Network. This medical provider network features handpicked physicians who receive extensive training in the same day procedures. We currently turn down many physicians who want to be part of this network for every physician we accept, choosing to grow the network more slowly with very high quality physicians. We now have about 25 US sites, all of which are independent medical practices. These practices also use our treatment registry, which has allowed us to collect more data we can report back to prospective patients.

In that same year, we were happy to welcome a philanthropic investment by John Malone, the largest US landholder. This investment allowed us to hire a separate Ph.D, level research staff and outfit a research only lab facility with all of the equipment you may find in a university stem cell lab. The focus of this research group is to work to continuously update the science behind the Regenexx procedures and to improve patient outcomes.

In summary, Regenexx is the longest running, most experienced, best published orthopedic stem cell therapy in the United States. We have collected more data on more treated patients than any other company. We’re dedicated to reinventing orthopedic care so that in the future, most patients can avoid invasive surgery.

Regenexx Online Media Room


We are committed to providing reliable, accurate and interesting news and information. If you don’t find what you need, contact us for information, ideas, resources, artwork, interviews or just answers to questions about Regenexx.

For press inquiries, please contact:
Mark Testa


Note to Reporters: The Regenexx procedures currently being offered in the US are 1271.15(b) compliant (same surgical procedure) and not considered a 351 drug by FDA. The only Regenexx procedure considered a drug by FDA was the Regenexx-C procedure, which has not been performed in the U.S. since 2010. For more information on the medical practice and it’s mission, click here.

-Wall Street Journal OpEds on Regenerative v. FDA: April 2012-Former FDA Commissioner Opposes FDA’s Stance, August 2012-Former FDA Deputy Director Opposes FDA’s Stance

-Manhattan Institute Legal Policy Review on How the FDA’s Misguided Regulation of Stem Cells Hurts Innovation

How We Educate Our Patients and the Public

We are leaders in stem cell research for orthopedics and we believe in following all of our patients in a treatment Registry and publishing the results of our therapies: the good results as well as the treatment failures. Here are some examples of easy to read patient infographics that provide these outcome details on many treated patients:

Patient Treatment Registry Outcome Data

We believe in highlighting both patient success stories and treatment failures. Here are example links to some treatment failures we have highlighted on our site: failure 1, failure 2


For our research articles published in medical research journals – Click Here

Press and News Coverage

No More Knife: The Stem-Cell Shortcut To Injury Recovery

Non-Surgical Treatment For ACL Injuries: A Quantum Shift In Medicine?

ESPN the Magazine Features Regenexx-C and Cayman Facility

Centeno-Schultz highlighted on ABC News / Good Morning America site.

More Questions? Search the Knowledge Base.

Share This